Clinical Trial

PSMA PET for the Staging and Management of Hepatocellular Carcinoma

Recruiting
View on ClinicalTrials.gov →
Summary
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-05; most recent amendment 2026-06-23.
Trial Details
NCT Number NCT07019844
Lead Sponsor VA Office of Research and Development
Collaborators: Miami VA Healthcare System, VA Medical Center-West Los Angeles
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 90 participants
Start Date 2024-09-19
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-26